AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 202 min read$TEM

Should You Be Worried About Tempus AI Stock?

Tempus AI (TEM) stock fell 17.3% in the past month, despite 22% quarterly sales growth. Its deal with AstraZeneca runs until at least 2026, possibly 2028, with potential revenue risks from pricing discounts. Data and Apps unit, 25% of sales, grew 28%. Tempus reported a $254M net loss, trading at 8.1x sales, down from 11.6x a year ago.

Original reporting
finance.yahoo.com
Published Oct 20, 2026, 11:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 11:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Should You Be Worried About Tempus AI Stock? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The extension of the AstraZeneca deal provides longer-term revenue visibility but introduces pricing uncertainty that could affect margins.

02

Market read

The news is material for Tempus AI shareholders due to contract length and pricing risk, with limited broader market impact.

03

What to watch

Potential competition from other AI data vendors and regulatory scrutiny of AI use in drug development.

Relevance 4/10Novelty 4/10Timing: post‑quarterly call

Background

Tempus AI is a biotech data company whose revenue heavily depends on licensing AI‑driven data to large pharmaceutical firms.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI disclosed that its data licensing agreement with AstraZeneca runs through 2028, extending the contract beyond 2026.

Expected impact

potential modest pressure as investors weigh margin risk versus longer-term revenue visibility

Evidence & confidence

Longer contract length supports revenue outlook, but discount risk could limit upside, leading to a balanced market reaction.

Market effects

Sector

Highlights growing reliance on AI data platforms in pharma, may spur interest in similar biotech data providers.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond the niche AI‑driven pharma data market.

Counterpoint

What could challenge this read

The pricing discount risk could erode margins more than the contract extension benefits, suggesting a downside bias.

Key entities

  • company
    Tempus AI

    US‑listed biotech data provider (ticker TEM).

  • company
    AstraZeneca

    Large pharmaceutical client of Tempus AI.

Read at source← All news

Related articles

OCT 26
$TEMMed

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

finance.yahoo.com2 min
OCT 26
$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

biospace.com3 min
OCT 24
$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

econotimes.com2 min
OCT 23
$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.

finance.yahoo.com2 min